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ABSTRACT
Many chemotherapeutic drugs cause nucleolar stress and p53-independent pathways mediating the
nucleolar stress response are emerging. Here, we demonstrate that ribosomal stress induced by
Actinomycin D (Act D) is associated to the up-regulation of ribosomal protein L3 (rpL3) and its
accumulation as ribosome-free form in lung and colon cancer cell lines devoid of p53. Free rpL3 regulates
p21 expression at transcriptional and post-translational levels through a molecular mechanism involving
extracellular-signal-regulated kinases1/2 (ERK1/2) and mouse double minute-2 homolog (MDM2). Our data
reveal that rpL3 participates to cell response acting as a critical regulator of apoptosis and cell migration. It
is noteworthy that silencing of rpL3 abolishes the cytotoxic effects of Act D suggesting that the loss of
rpL3 makes chemotherapy drugs ineffective while rpL3 overexpression associates to a strong increase of
Act D-mediated inhibition of cell migration. Taking together our results show that the efﬁcacy of Act D
chemotherapy depends on rpL3 status revealing new speciﬁc targets involved in the molecular pathways
activated by Act D in cancers lacking of p53. Hence, the development of treatments aimed at upregulating
rpL3 may be beneﬁcial for the treatment of these cancers.
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Introduction
The main role of the nucleolus is the production of small and
large ribosome subunits, but it appears to be involved in addi-
tional cellular functions that may not be directly related to ribo-
some subunit biogenesis.1,2 The protein content of the nucleolus
is dynamic and alters under stress condition.2,3 In eukaryotes,
ribosome biogenesis is a complex process that requires a num-
ber of coordinate events prior to nuclear export of the mature
subunits to the cytoplasm.4 In growing and proliferating tumor
cells, the process of ribosome biogenesis is enhanced compared
with normal somatic cells5 suggesting that tumor cells are more
sensitive to nucleolar stress than normal cells. Thus, chemother-
apeutic agents that selectively target ribosome biogenesis could
be less toxic to normal and differentiated cells. Moreover, unlike
traditional anti-cancer drugs such as cisplatin and doxorubicin
that are genotoxic, they did not cause DNA damage. Several
anti-cancer agents that speciﬁcally inhibit RNA Pol I inducing
nucleolar stress have been identiﬁed.6,7 Among these, Actino-
mycin D (Act D), a widely used anti-cancer drug, is the best
example of nucleolar stress-inducing chemical agents. Low
doses of Act D (<10 nM) have been shown to exclusively inhibit
RNA Polimerase I activity, leading to impaired ribosomal RNA
(rRNA) transcription.8The mode of action and speciﬁc targets
involved in the molecular pathways activated by Act D are less
deﬁned. The identiﬁcation of the cellular targets of a chemother-
apeutic drug is an important challenge for the improvement of
therapy regimens for cancer treatment. Perturbations in pro-
cesses such as rRNA synthesis, rRNA modiﬁcation as well as
ribosomal protein (r-protein) imbalance produce alterations in
ribosome biogenesis and resulting in nucleolar stress, causing
an accumulation of ribosome-free form of r-proteins.9-11 In
response to this event some r-proteins translocate from the
nucleolus to the nucleoplasm where bind to (mouse double min-
ute-2 homolog) MDM2 thus promoting p53 stabilization and
subsequent p53 mediated cell cycle arrest or apoptosis.12 Recent
ﬁndings revealed novel stress response pathways, which func-
tion independently of p53 and still lead to cell cycle arrest
and/or apoptosis. Given that most cancers lack functional
p53, it is of great importance to study these emerging molecular
mechanisms. p53-independent pathways that require nucleolar
proteins, such as Nucleophosmin (NPM), free r-proteins or
MDM2 have also been identiﬁed.13 It has been demonstrated
that the expression of p21 protein, a cyclin-dependent kinase
inhibitor (CKI), is negatively regulated by MDM2 protein inde-
pendently of p53.14,15 Recently, we demonstrated that ribo-
some-free rpL3 plays a crucial role in cell response to nucleolar
stress induced by anticancer drugs known to interfere with
DNA metabolism, but also able to act on RNA metabolism.
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Indeed, the rpL3 absence is dramatically associated to drug
ineffectiveness.16
In this paper we investigated the regulatory mechanism of
p21 expression mediated by rpL3 upon Act D-induced nucleo-
lar stress. We show that rpL3 is involved in drug-induced apo-
ptosis and inhibition of cell proliferation and migration by
controlling p21 expression both at transcriptional and post-
translational levels independently from p53. We identify ERK
1/2 and MDM2 as new molecular targets of rpL3. Our ﬁndings
extend the scenario of mechanisms involved in tumor cell
response to drugs that speciﬁcally impact ribosome biogenesis
for the treatment of cancers lacking active p53.
Results
Act D increases the intracellular levels
of ribosome-free rpL3
It has been previously demonstrated that low doses of Act D
(5 nM) exclusively inhibits RNA polymerase I-driven transcrip-
tion17 and induces ribosomal stress. In order to study the alter-
ation of rpL3 and p21 expression in condition of ribosomal
stress, Calu-6 and HCT 116 p53-/- cells were treated or not with
5 nM of Act D for 24 h. Then, cells were lysated and protein
extracts were analyzed by western blotting with anti-rpL3, anti-
p21, anti-rpL7a, anti-rpS19 and anti a-tubulin. The results dem-
onstrated that Act D treatment induced a speciﬁc increase of
rpL3 levels that was associated to higher intracellular amounts
of p21. No changes were observed in the expression levels of
rpL7a and rpS19, 2 arbiratry ribosomal proteins of large and
small subunits, respectively (Fig. 1A-B). To understand whether
Act D-induced upregulation of rpL3 was also associated to its
release from the ribosome, we treated Calu-6 cells with 5 nM of
Act D or not. Then cells were collected, lysated (total fraction,
TF) and fractionated to obtain the ribosome-associated fraction
(RF) and the ribosome-free fraction (FF).16 Proteins extracted
from each fraction were analyzed by western blotting with anti-
rpL3, anti-rpL7a, anti-rpS19, anti-rpL11 and anti-b-actin. The
results demonstrated that Act D treatment caused a signiﬁcant
increase of ribosome-free rpL3 level wherease it failed to increase
the levels of the arbitrary rpL7a and rpS19, which remained
largely associated to the ribosome (Fig. 1C).
rpL3 regulates p21 gene transcription upon
Act D treatment
Calu-6 and HCT 116 p53-/- cells, untreated or treated with
5 nM of Act D for 24 h, were collected and subjected to Chro-
matin immunoprecipitation experiments by using anti-rpL3
and anti-IgG as control. The presence of rpL3 in DNA-immu-
noprecipitated complexes was assayed by western blotting.
qPCR assay on the samples was performed as previously
reported.16 Figure 2 shows that in untreated cells, rpL3 is able
to bind p21 promoter, as we previously demonstrated.16 After
Act D treatment, the binding of rpL3 on p21 promoter was sig-
niﬁcantly increased compared to that observed in the control.
Next, to test the role of rpL3 on p21 promoter activity in the
response to drug exposure, we performed a reporter luciferase
assay in condition of rpL3 silencing and drug treatment. To
this aim, Calu-6 and HCT 116 p53-/- cells were transiently
cotransfected with the full-length p21 promoter luciferase
reporter plasmid and siRNA speciﬁc for rpL3 (rpL3-siRNA) or
scrambled siRNA (Src-siRNA). Then, cells were treated with
5nM of Act D for 24 h or untreated and analyzed by western
blotting with anti-rpL3 and anti-p21 (Fig. S1). As shown in
Fig. 2C-D in untreated cells the rpL3 silencing did not cause
any signiﬁcant alteration on p21 promoter activity compared
to untreated cells transfected with scrambled siRNA. The treat-
ment with Act D increased p21 gene promoter activity. When
rpL3 expression was switched off, the effect on p21 gene tran-
scription of Act D was completely abolished since p21 pro-
moter activity was similar to that observed in the control
(Fig. 2C-D). These data indicated that rpL3 was necessary for
regulating p21 promoter activity in the cell response to Act D.
rpL3 interacts with p21 in vivo and in vitro and positively
regulates p21 half-life
The translocation of rpL3 from the nucleolus to the nucleo-
plasm under ribosomal stress drove us to explore whether the
subcellular localization change of rpL3 favored its interaction
with p21 protein. To this aim, Calu-6 cells were collected and
subjected to co-immunoprecipitation experiments. rpL3 was
speciﬁcally immunoprecipitated from protein extracts. Then,
the obtained immunocomplexes were analyzed by western blot-
ting using anti-rpL3 and anti-p21. The presence of p21 in the
rpL3-immunoprecipitate was consistent with a speciﬁc associa-
tion between rpL3 and p21 in vivo. A control immunoprecipi-
tate obtained with anti-IgG antibodies did not give any signal
when probed with anti-rpL3 or anti-p21 (Fig. 3A).
To further analyze the interaction between rpL3 and p21, we
performed GST pull-down assay by using puriﬁed recombinant
proteins. His-tagged proteins rpL3 and NPM as control (His-
rpL3 and His-NPM, respectively) were tested for their ability to
bind to immobilized GST-tagged p21 (GST-p21). GST-p21,
and GST as control, were immobilized using GSH-sepharose
beads and incubated with puriﬁed His-rpL3 and His-NPM.
Western blot analysis was performed on each pull-down sam-
ple. Fig. 3B shows that His-rpL3 was revealed in the pull-down
preparation of GST-p21, but not in that of GST. These results
provide evidence for a direct binding between rpL3 and p21 in
vitro. No interaction was detected with GST-rpL7a used as a
further control (data not shown).
p21 is a short-lived protein and post-translational regulations
play a critical role in p21 expression.18 On the basis of interac-
tion between rpL3 and p21, we explored the possibility that rpL3
could regulate p21 amounts also at post-translational level.
Therefore, in order to assess whether rpL3 affects the turnover
of p21 we performed the analysis of p21 half-life in condition of
alteration in rpL3 expression. To this aim, we generated a cell
line stably silenced for rpL3 derived from Calu-6 cells namely
rpL3DCalu-6 cells. Fig. S2 shows the decrease of rpL3 levels in
different obtained clones. We chosed the cell clone expressing
the lowest level of rpL3 for further experiments. Thus, Calu-6
and rpL3DCalu-6 cells were treated with 5nM of Act D for 24 h
and exposed to 10 mg/ml of the inhibitor of protein synthesis
Cyclohemide (CHX) for different times (0, 0.5, 1, 1.5 and 2 h).
Protein extracts from the samples were analyzed by western
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blotting using antibodies against p21. Fig. 3C showed that the
half-life of p21 was greater in Calu-6 cells upon exposure to Act
D (1 h vs 1.5 h). Of interest, in rpL3DCalu-6 cells the silencing of
rpL3 impaired the upregulation of p21. These data clearly dem-
onstrate that rpL3 positevely affect p21 stability and suggest that
in condition of drug-induced nucleolar stress rpL3 becomes a
positive regulator of p21 half-life.
rpL3 regulation of p21 involves pERK and MDM2
As reported in the literature, p21 expression is mainly a result of
ERK activation in a number of cell types.19,20 Recent ﬁndings dem-
onstrated that Raf/MEK/ERK activates Sp1-mediated p21 promoter
activity in p53 null cells21. It has also been demonstrated that p21
protein expression is negatively regulated by MDM2 protein inde-
pendently of p53.15 These ﬁndings prompted us to analyze whether
ERK1/2 and MDM2 could play a role in rpL3-induced regulation
of p21 expression. To this aim, we analyzed the effects of the alter-
ation in the expression levels of rpL3 on the poshorylated ERK and
MDM2 protein levels. Calu-6 cells, untransfected or transiently
transfected with pHA-rpL3 for 24 h, and rpL3DCalu-6 cells were
treated or not with 5 nM of Act D. Twenty-four h later, cells were
lysated and protein extracts were analyzed by western blotting with
anti-pERK, anti-p21 and anti-rpL3.
Fig. 4A shows that Act D treatment did not cause any
changes in pERK levels. When rpL3 was overexpressed in
untreated and Act D-treated cells a strong increase in the phos-
phorylation of ERK was detected. According to this, in
untreated or treated cells the silencing of rpL3 inibithed the
activation of ERK. These results clearly indicate that rpL3 posi-
tively affects the phosphorylation of ERK. As expected, the acti-
vation of pERK was associated to an increase of p21.
Figure 1. Expression proﬁles of rpL3 and p21 in Calu-6 and HCT 116 p53-/- cells upon Act D treatment. (A) Calu-6 and (B) HCT 116 p53-/- cells were treated with 5 nM of
Act D for 24 h or untreated. Protein extracts from untreated or treated cells were analyzed by western blotting with indicated antibodies. Anti-a-tubulin was used as load-
ing control. Quantiﬁcation of protein levels is shown. (C) Ribosome distribution proﬁle of rpL3 protein upon Act D treatment. Calu-6 cells, untreated and treated with 5 nM
of Act D for 12 and 36 h were collected, lysated (total fraction, TF) and fractionated to obtain the ribosome-associated fraction (RF) and ribosome-free fractions (FF).
The fractions were analyzed by western blotting with the indicated antibodies. The per-cell ratio of the amount of protein loaded onto a gel was TF:RF:FF/1:10:1.
Quantiﬁcation of rpL3 protein levels in FF (panel on the right) is shown. Results illustrated in Figures 1–6 are representative of 3 independently performed experiments.
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Moreover, by examining MDM2 levels, we observed that Act
D treatment induces an increase of MDM2 intracellular
amounts while the enforced expression of rpL3 impairs Act
D-mediated MDM2 upregulation. In rpL3 depleted cells an
increase in MDM2 levels was observed (Fig. 4A) and this effect
was stronger upon Act D tretament. Of note, the upregulation
of MDM2 was associated to a decrease in pERK and p21
protein levels. It is known that MDM2 is a negative regulator of
p21. Since rpL3 overexpression correlates to MDM2 downregu-
lation and p21 upregulation we hypothesized that rpL3 could
regulate p21 stability by modulating the interaction between
p21 and its negative regulator MDM2. An attractive possibility
was that rpL3 might stabilize p21 by abrogation of MDM2-p21
interaction. Thus, we looked for MDM2 in rpL3 immunopreci-
pitated complexes. The absence of signal for MDM2 in the
immunoprecipitates demonstrated that rpL3 and MDM2 did
not associate in vivo (Fig. S3). Furtermore, we veriﬁed whether
rpL3 could regulate MDM2 expression acting as transcriptional
factor. To this aim we analyzed MDM2 mRNA levels upon
alteration in rpL3 expression levels and Act D treatment. No
change in MDM2 mRNA amounts in all tested conditions was
observed indicating that rpL3 is not involved in the regulation
of MDM2 expression at trasncriptional levels in normal condi-
tion or in condition of nucleolar stress (Fig. S4). These data
Figure 2. Analysis of the interaction between rpL3 and p21 gene promoter in response to ActD treatment. Protein samples of DNA-rpL3 or DNA-IgG immunocomplexes
from (A) Calu-6 cells and (B) HCT 116 p53-/- untreated or treated with 5 nM Act D for 24 h were analyzed by western blotting assay with antibodies against rpL3. Note
the absence of signal in DNA-IgG immunocomplex. The same DNA-immunoprecipitates were subjected to qPCR with primers speciﬁc for the proximal region of p21 gene
promoter or control loci (p21 3’-UTR). (C) Calu-6 cells and (D) HCT 116 p53-/- cells were transiently cotransfected with the full-length p21 promoter luciferase reporter
plasmid and siRNA speciﬁc for rpL3 (rpL3-siRNA) or scrambled siRNA (Scr-siRNA). Then, cells were treated with 5 nM of Act D for 24 h or untreated. Analysis of the
relative luciferase activity, normalized against Renilla Luciferase (pRL) activity, of the samples is shown.
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suggest that a more complex mechanism of regulation remains
to be clariﬁed.
To better understand whether pERK was required for the
rpL3-mediated induction of p21 expression, we treated cells
with MEK1/2 inhibitor (PD18). To this aim, Calu-6 cells were
transiently transfected with pHA-rpL3. Twenty-four h later,
untransfected and transfected cells were treated with 10 mM of
the inhibitor PD18 for 1 and 3 h. Then, cell were collected,
lysated and protein extracts were analyzed by western blotting.
As shown in Figure 4B, the addition of PD18 inhibited ERK
phopshorylation. Of interest, the ectopic expression of rpL3
was able to overcome PD18 inhibition suggesting that rpL3 was
crucial for ERK phosphorylation.
rpL3 is involved in cell response to ribosomal stress
induced by Act D
To study the involvement of rpL3 on cell response to ribosomal
stress induced by Act D, we ﬁrstly analyzed the inﬂuence of
rpL3 on cell proliferation. To this aim, Calu-6 and rpL3DCalu-
6 cells were treated with 5 nM of Act D for 24 h. In Calu-6 cells,
the colony number was reduced upon exposure to Act D thus
conﬁrming the ability of the drug to inhibit clonogenicity. It is
noteworthy that in rpL3DCalu-6 cells the capacity of cells to
produce colonies upon Act D treatment was comparable to the
capacity of untreated rpL3DCalu-6 cells (Fig. 5A). These results
suggest that the loss of rpL3 plays an important role in inhibi-
tion of cell proliferation upon exposure to Act D.
To study the effect of rpL3 on ActD-induced apoptosis, Calu-
6 and rpL3DCalu-6 cells were treated with 5 nM of ActD or not.
Twenty-four h later, modiﬁcations of mitochondrial inner mem-
brane were estimated by tetramethylrhodamine (TMRE) stain-
ing and analyzed by ﬂow cytometry. As expected, the percent of
apoptosis increased after Act D treatment but, of note, rpL3
silencing caused a decrease of apoptotic cell number following
Act D exposure (Fig. 5B). Having established the key role of
rpL3 in cell response to Act D treatment, we wondered whether
rpL3 overepression could improve the cytotoxic effects of Act D.
To this aim, we evaluated the in vitro cytotoxicity of Act D in
combination with rpL3 overexpression. Calu-6 cells, untrans-
fected and transiently transfected with pHA-rpL3, were treated
with 5nM of Act D. Twenty-four h later, the cytotoxicity was
evaluated by using MTT assay. Figure 5C shows that in Act D
treated cells the cytotoxicity induced by rpL3 overexpression
Figure 3. Analysis of the interaction between rpL3 and p21 proteins upon Act D treatment in vivo. (A) rpL3 was speciﬁcally immunoprecipitated from Calu-6 cells extracts
with antibodies against the endogenous rpL3. Immunoprecipitates were separated by SDS–PAGE and immunoblotted with antibodies versus the indicated proteins. Note
the absence of signal in IgG immunocomplex. (B) Analysis of the interaction between rpL3 and p21 proteins in vitro. GST-p21 or GST (control), were immobilized on gluta-
thione-sepharose beads and incubated with His-rpL3 or His-NPM. The eluted proteins were then analyzed by immunoblot with antibodies anti-rpL3 and anti-NPM. Note
the absence of signal in control GST pull-down preparations. (C) Effect of rpL3 on p21 half-life. Calu-6, rpL3DCalu-6 and Calu-6 cells treated with 5 nM of Act D for 24 h
were incubated with CHX for the indicated times. Western blot was performed using anti-p21 antibody and anti-b-actin as loading control.
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was increased of about 20–25% as compared with cells treated
with Act D alone suggesting that the ectopic expression of rpL3
allowed a more potent antiproliferative activity.
Furthermore, considering that rpL3 overexpression was
associated to the upregulation of p21 and the role of p21 in pre-
venting cell migration, we became interested to investigate
the effect of rpL3 overexpression on cell motility. Calu-6 cell
migration was determined using wound healing assay and
quantitatively evaluated in terms of occupation rate of open
wound As indicated in Fig. 6, the wound healing ability of Act
D treated Calu-6 cells was reduced in time dependent manner
compared to that observed in untreated cells. Likewise, the
quantitative analysis showed that the open wound of Act D
treated Calu-6 cells was increased of about 20% and 30% com-
pared to untreated cells after 8 and 24 h, respectively. When
rpL3 was overexpressed, the wound healing ability of Act D
treated Calu-6 cells was markdely reduced, demonstrating that
rpL3 overexpression was able to furher decrease Act D-reduced
cell motility. In particular, the quantiﬁcation indicated that the
open wound of Act D treated Calu-6/rpL3 cells and overex-
pressed of rpL3 was further increased of about 10% and 35%
compared to that of Act D-treated cells after 8 and 24 h, respec-
tively (Fig. 6).
Discussion
Ribosome biogenesis is a complex process, highly regulated,
and represents one of the major energy consuming processes of
the cell.22 The control of ribosome biogenesis is critical for cell
cycle progression, cell growth and cell proliferation.23 Perturba-
tion in ribosome synthesis causes ribosomal stress with conse-
quent release of nucleolar and ribosomal proteins that
participate in a surveillance mechanism, regulating the cellular
function of the critical tumor suppressor protein p53.1 In
human tumors, the disruption of p53 function represents the
most frequent gene alteration and this occurs in more than
50% of cancers.24 Recently, several p53-independent pathways
that cause cell cycle arrest or apotptosis in response to altera-
tions of ribosome biogenesis have been described.25,26 Several
ﬁndings have shown evidence that a variety of DNA damage
agents including 5-FU and L-OHP impair ribosomal biogene-
sis.16,27 We have recently demonstrated that human rpL3 acts
as stress sensing molecule essential in the cell response to ribo-
somal stress caused by 5-FU and L-OHP in cancer cells lacking
active p53.16 In this scenario, our effort has been directed
toward the study of p53 independent pathways activated upon
Act D induced ribosomal stress in order to reveal new aspects
of well studied chemothepeutic drug and/or new therapeutic
targets in the therapy of p53-negative cancers.
The antineoplastic antibiotic Actinomycin D represents one
of the older clinically approved drug used to treat gestational
trophoblastic cancer, testis cancer, Wilm’s tumor, rhabdomyo-
sacoma and Ewing’s sarcoma.28 It is known that Act D, at a low
cytostatic concentration, is speciﬁcally able to trigger ribosomal
stress.29 Although low doses of Act D have been studied in p53
cell system, it has been demonstrated that the selective inhibi-
tion of rRNA synthesis by Act D was able to cause a perturba-
tion of cell cycle progression also in cells silenced of p53, but
the molecular pathways by which this occurs has not been
determined.9
Here we show that low doses of Act D (5 nM) induce the
expression of rpL3 and its release from the ribosome in p53
mutated and p53 negative cells (Fig. 1). Data from the ChIP
experiments and reporter luciferase assays reported here showed
that upon Act D treatment free rpL3 binds p21 promoter and
positively affects p21 expression at transcriptional level (Fig. 2).
Analysis of immunoprecipitate of rpL3 in p53 null cells showed
that rpL3 and p21 coimmunoprecipitate together indicating that
Figure 4. Inﬂuence of rpL3 on MDM2, pERK1/2 and p21 proteins upon Act D treat-
ment. (A) Calu-6 cells were transiently transfected with pHa-rpL3. Calu-6, Calu-6/
rpL3 and rpL3DCalu-6 were treated with 5 nM Act D for 24 h or untreated. Protein
extracts from the samples were analyzed by western blot with indicated antibod-
ies. Anti-vinculin was used as loading control. (B) Effect of rpL3 on ERK expression
upon ERK inhibition. Calu-6 cells were transiently transfected with pHA-rpL3. 24 h
later, untransfected and transfected cells were treated with 10 mM of the inhibitor
PD18 for 1 and 3 h. Protein extracts from the samples were analyzed by western
blot using anti-ERK1/2 and pERK1/2 antibodies. Anti-b-tubulin was used as loading
control.
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these proteins associate in vivo. In addition, a direct binding
between these 2 proteins was observed in vitro by performing
GST pull-down experiments (Fig. 3A and B). These results led
us to hypothesize that the speciﬁc interaction between pL3 and
p21 could affect p21 stability. We demonstrated that in cell sta-
bly depleted of rpL3, the half life of p21 was decreased, while
ActD mediated rpL3 upregulation associates to a marked
increase in p21 half life (Fig. 3C). These results indicate that
rpL3 prolongs the half life of p21
As expected, Act D treatment of Calu-6 cells caused an
increase in the number of apoptotic cells. Of interest, the spe-
ciﬁc rpL3 impairment was able to markedly reduce the cyto-
toxic effects of the drug. In fact when rpL3 expression was
switched off (rpL3DCalu-6 cells) we observed a strong reduc-
tion in the percentage of apoptotic cells (10% vs 40%) following
drug incubation and the cells became more resistant to Act D
treatment (Fig. 5A and B). In addition, the ectopic expression
of rpL3 strongly increased Act D mediated cytotoxic effects
(Fig. 5C). Taken togheter, these results suggest that rpL3 exerts
itself a cytotoxic activity that could be exploited to enhance the
susceptibility of speciﬁc tumors lacking of p53 to the treatment
with Act D. Furthermore, our studies demonstrate that rpL3-
mediated upregulation of p21 contributes to the inhibition of
cell migration (Fig. 6).
Next, we identiﬁed MDM2 and ERK 1/2 as a new molecular
targets of rpL3 (Fig. 4). Speciﬁcally, we demonstrated that rpL3
was able to inhibit Act D mediated MDM2 upregulation. The
observed increased levels of MDM2 in cells treated with Act D
and silenced of rpL3 correlated to decreased amounts of p21
protein. This result together with previous data indicating that
p21 protein expression is negatively regulated by MDM2 pro-
tein independently of p5314,15 led us to hypothesize that rpL3 is
crucial for the regulation of p21 protein levels after Act D treat-
ment by regulating MDM2-mediated stability of p21.
It is known that MEK/ERK pathways control the growth and
survival of a large spectrum of human cancers30 and affect p21
expression.31 MEK1/2 is immediately upstream of ERK1/2 and
has been reported to activate ERK1/2. The use of speciﬁc MEK
inhibitor allowed us to selectively inhibit ERK1/2 activation
thereby showing that ERK pathway represents the key mecha-
nism of rpL3-mediated cell response (Fig. 4B). The proapoptotic
function of the ERK pathway is well documented for apoptosis
induced by DNA-damaging agents.32 ERK activity has been par-
ticularly implicated in cisplatin-mediated apoptosis.33 Mecha-
nisms of ERK-mediated apoptosis include the upregulation of
p53 associated to an increase of its stability by inhibiting the
association with MDM2.34 However, some studies have shown
that ERK is also able to induce apoptosis independently of p53.35
All together our results led us to propose a working model
predicting that Act D-induced ribosomal stress causes the upre-
gulation of rpL3 expression and its dissociation from the ribo-
some. The increased ribosome-free form of rpL3 (free rpL3)
translocates from nucleolus to nucleus where takes part to
the transactivation of p21 promoter (Fig. 7).25,36 We have
Figure 5. (A) Representative image of clonogenic analysis for cell proliferation in Calu-6 and rpL3DCalu-6 cells after Act D treatment. Bar chart indicating clonogenic
growth is shown. (B) Role of rpL3 on apoptosis upon Act D treatment. Calu-6 and rpL3DCalu-6 were treated with 5 nM of Act D for 24 h or untreated. Then, cells were ana-
lyzed for mitochondrial membrane potential by TMRE staining and analyzed by ﬂow cytometry. (C) Role of rpL3 on cell viability upon Act D treatment. Cell viability of
untreated or Act D treated Calu-6 cells and Calu-6 cells transiently transfected with pHA-rpL3 was evaluated using the MTT assay. The cell viability was calculated vs
untreated control cells at the respective time of incubation, set as 100%. Results are presented as percentage (mean § ds) (n D 3) of the control cells.
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previously reported that rpL3-mediated p21 upregulation
requires the speciﬁc interaction between rpL3 and Sp1.36 It has
been shown that ERK1/2 is involved in p21 dependent G1 cell
cycle arrest37 and that ERK1/2 can phosphorylate Sp1 on
Threonines 453 and 739 in vitro and in vivo.21 These Sp1 phos-
phorylations were also detected when perifosine induced
p21CIP1 transcription via MEK/ERK.21Here, we show that the
ectopic expression of rpL3 is able to induce the phosphoryla-
tion of ERK, thereby activating ERK, essential in mediating
rpL3-induced p21 expression. Based on these observations, we
can speculate that the MEKs/ERKs pathway activated by free
rpL3 could induce, in turn, the phosphorylation of Sp1 and
promotes Sp1/rpL3 binding to the p21 promoter. These ﬁnd-
ings indicate that when overexpressed upon Act D induced
nucleolar stress rpL3 becomes an inducer of p21 via ERK acti-
vation (Fig. 7). Furthermore, the ﬁnding that the increased
ribosome-free rpL3 was associated to MDM2 downregulation
and p21 upregulation led us to propose that rpL3 could modu-
late p21 stability by controlling the interaction between p21
and its negative regulator MDM2. rpL3 effects associate to cell
cycle arrest, apoptosis and inhibition of cell proliferation and
migration (Fig. 7).
In conclusion our ﬁndings provide new insigth for the devel-
opment of novel therapeutical strategy to improve the efﬁcacy
of clinically approved drugs that speciﬁcally impact ribosome
biogenesis in the treatment of cancers lacking active p53.
Materials and methods
Cell cultures, transfections and drug treatment
Human Calu-6 and HCT 116 p53-/- cell lines were cultured in
Dulbecco’s Modiﬁed Eagle’s Medium (DMEM) with glutamax
(Invitrogen) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine, penicillin-streptomycin 50 U/ml and
0.1 mM non-essential amino acids (Euroclone).
rpL3DCalu-6 cell line was obtained from Calu-6 cells. Cells
were transfected with 2 mg of different shRNA rpL3 plasmids
(Sigma-Aldrich) by using Lipofectamin 2000 (Life Technolo-
gies) according to the manufacturer’s instructions. Stable clones
were selected in medium containing 1 mg/ml of Puromicin
(Sigma-Aldrich) and assayed for the detection of rpL3 expres-
sion level by western blotting.
Transfection of DNA, siRNA and shRNA targeting rpL3
(Sigma-Aldrich) was performed in cells using Lipofectamin
2000 as previously described.38
Drug treatments were performed by adding to cells 5 nM of
Actinomycin D (Act D, Sigma-Aldrich) for 24 h.
Ribosome isolation
Ribosome isolation was performed as previously reported.39
Figure 6. Role of rpL3 on cell migration upon Act D treatment. Calu-6 cells
untransfected or transiently transfected with pHa-rpL3 were treated with 5 nM of
Act D for 24 h. Wound widths were measured at 0, 8 and 24 h on 3 ﬁelds per well
and averaged. Data is expressed as the fold-decrease of area respect to controls
(A,D,G) set as 100%. Bars represent the mean of triplicate experiments; error bars
represent the standard deviation.
Figure 7. Schematic representation of proposed model. Act D induced nucleolar stress caused an induction of rpL3 total intracellular levels and the accumulation of rpL3
as ribosome-free form. Free rpL3 becomes a regulator of p21 expression. At transcrptional level, rpL3 induces the phosphorylation of ERK that, in turn, could promote the
phosphorylation of Sp1. Then, rpL3 could recruit phosphorylated Sp1 and induce the transactivation of p21 promoter. At post-translational level, rpL3 binds and stabilizes
p21 protein and downregulates MDM2. rpL3 effects associate to cell cycle arrest, apoptosis and inhibition of cell proliferation and migration.
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Plasmids and production of recombinant proteins
Plasmids encoding pHA-rpL3 and pGL3 control plasmid were
already available. The recombinant proteins GST-rpL3, GST-p21,
His-rpL3 and His-NPMwere produced as previously reported.39
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIp) assay was performed
as previously reported.16
Dual luciferase assay
Luciferase assays were performed as previously reported.16
GST pull-down and Immunoprecipitation assay
GST pull-down assay was performed as previously reported.40
p21 half-life analysis
Cells were treated with 5 nM Actinomycin D for 24 h or
untreated. Then, cells were treated with Cycloheximide (CHX)
0,1 mg/ml for different times, and subsequently harvested and
lysed using RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 1%
NP40, 0,5% Na-deoxycolate, 150 mM NaCl, 1 mM Na3VO4,
1 mM NaF, 1X EDTA-free Roche protease inhibitor cocktail).
Protein extracts from samples were analyzed by western blotting.
Western blotting
Western blotting analysis was performed as previously
reported.41 The membranes were challenged with anti-rpL3
and anti-rpL7a (Primm), anti-p21 (BD Pharmingen), anti-
rpS19, anti-p70S6k, anti-anti-vinculin, anti-b-actin and anti-
HA-Tag (Santa Cruz Biotechnology), anti pERK 1/2 and anti-
ERK 1/2 (Cell Signaling Technologies). Anti-MDM2 antibodies
were kindly provided by Fabiola Moretti (CNR-Santa Lucia).
Proteins were visualized with enhanced chemiluminescence
detection reagent according to the manufacturer’s instructions
(Millipore).
Mitochondrial membrane potential measurement
To quantify changes in mitochondrial membrane potential,
cells were labeled with 50 nM of the mitochondrial membrane
potential-sensitive ﬂuorescent dye tetramethylrhodamine ethyl
ester (TMRE, Invitrogen) for 30 min at 37 C and analyzed by
ﬂow cytometry.
3-(4,5-Dimethylthiazole-2-yl)-2,5-biphenyltetrazolium
bromide (MTT) assay
MTT assay was performed as previously described.42
Clonogenic assay
For clonogenic assay, cells (4 £ 103 in 6-well multidishes) were
plated in triplicate and treated with 5nM of Act D for 24 h or
not. After 5 to 7 days, colonies were stained with 1% methylene
blue in 50% ethanol.
Wound healing assay
Cell motility was assessed using a wound healing assay. Calu-6
cells (1 £ 106 per well) were seeded into 35 mm tissue culture
plates and transiently transfected with pHa-rpL3. After 48 h,
Calu-6 cells were treated with Act D 5 nM for 24 h or not. The
conﬂuent monolayer cells were then carefully wounded using a
sterilized pipette tip. Monolayer cells were photographed at 0, 8
and 24 h with an objective 10X. Quantitative analysis of wound
assay was performed by measuring the gap area. The gap area
was deﬁned by using ImageJ Software (National Institute of
Health, USA). Data is expressed as the fold-decrease of area
respect to controls set as 100%. Bars represent the mean of trip-
licate experiments; error bars represent the standard deviation.
Abbreviations
Act D Actinomycin D
CHX Cycloheximide
CKI cyclin-dependent kinase inhibitor
ERK extracellular-signal-regulated kinase
FACS ﬂuorescence-activated cell sorting
FBS fetal bovine serum
GST glutathione S-transferase
HA hemagglutinin
His histidine
L-OHP Oxaliplatin
MEK Mitogen-activated protein/Extracellular signal-reg-
ulated Kinase
MDM2 Mouse double minute-2 homolog
NPM nucleophosmin
r-proteins ribosomal proteins
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